US Bancorp DE cut its holdings in shares of Balchem Co. (NASDAQ:BCPC – Get Rating) by 2.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,727 shares of the basic materials company's stock after selling 408 shares during the quarter. US Bancorp DE owned about 0.06% of Balchem worth $2,560,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of BCPC. Advisor Group Holdings Inc. grew its holdings in shares of Balchem by 4.2% during the 4th quarter. Advisor Group Holdings Inc. now owns 5,264 shares of the basic materials company's stock worth $887,000 after purchasing an additional 211 shares during the period. American Century Companies Inc. purchased a new position in Balchem during the 4th quarter valued at about $671,000. First Trust Advisors LP boosted its holdings in Balchem by 87.4% during the 4th quarter. First Trust Advisors LP now owns 63,774 shares of the basic materials company's stock valued at $10,752,000 after acquiring an additional 29,749 shares during the period. CIBC Asset Management Inc purchased a new position in Balchem during the 4th quarter valued at about $213,000. Finally, Raymond James & Associates boosted its holdings in Balchem by 1.1% during the 4th quarter. Raymond James & Associates now owns 38,228 shares of the basic materials company's stock valued at $6,445,000 after acquiring an additional 422 shares during the period. 89.15% of the stock is currently owned by hedge funds and other institutional investors.

Balchem Price Performance

BCPC stock opened at $130.43 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.62 and a quick ratio of 1.64. The firm has a market capitalization of $4.19 billion, a P/E ratio of 39.05 and a beta of 0.59. The business's 50-day moving average is $131.41 and its two-hundred day moving average is $130.21. Balchem Co. has a 1 year low of $110.15 and a 1 year high of $174.29.

Insider Buying and Selling at Balchem

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BCPC shares. StockNews.com cut Balchem from a "buy" rating to a "hold" rating in a report on Monday, August 1st. HC Wainwright increased their price target on Balchem from $152.00 to $164.00 and gave the company a "buy" rating in a research report on Monday, August 22nd.

Balchem Company Profile

(Get Rating)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

Read More

• Get a free copy of the StockNews.com research report on Balchem (BCPC)
• Could Nike Stock be Oversold, but Still Overvalued?
• Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
• Will Royal Caribbean's Broadband Partnership Drive Revenue?
• Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
• DocuSign Has Important Issues to Address When it Reports Earnings

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.